GW Pharmaceuticals Stock Price Target and Analyst Ratings (NASDAQ:GWPH)

Analyst Price Target for GWPH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$188.09

▲ +38.58% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for GW Pharmaceuticals in the last 3 months. The average price target is $188.09, with a high forecast of $275.00 and a low forecast of $128.00. The average price target represents a 38.58% upside from the last price of $135.73.

Buy

The current consensus among 12 contributing investment analysts is to buy stock in GW Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/25/2019

0 strong buy ratings
12 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/23/2019

0 strong buy ratings
12 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/21/2020

0 strong buy ratings
14 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/20/2020

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/19/2020

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/17/2020

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/16/2020

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/15/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
12/29/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$165.00 ➝ $147.00	N/A	i
11/4/2020	HC Wainwright	Reiterated Rating	Buy		Low	i Rating by D. Tsao at HC Wainwright
8/24/2020	Raymond James	Initiated Coverage	Market Perform		High	i
8/10/2020	Guggenheim	Lower Price Target	Buy	$160.00 ➝ $155.00	Medium	i
8/7/2020	The Goldman Sachs Group	Set Price Target	Buy ➝ In-Line	$171.00 ➝ $271.00	High	i Rating by Salveen Richter, CFA at The Goldman Sachs Group, Inc.
8/7/2020	Bank of America	Reiterated Rating	Buy	$234.00	High	i
8/7/2020	Needham & Company LLC	Lower Price Target	Buy	$190.00 ➝ $180.00	High	i
8/4/2020	HC Wainwright	Boost Price Target	Buy	$161.00 ➝ $164.00	Medium	i
8/3/2020	Oppenheimer	Reiterated Rating	Buy	$166.00 ➝ $183.00	Medium	i Rating by Francois Brisebois at Oppenheimer Holdings Inc.
8/3/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$160.00 ➝ $165.00	Low	i Rating by C. Duncan at Cantor Fitzgerald
7/14/2020	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$150.00 ➝ $140.00	High	i
6/30/2020	Evercore ISI	Boost Price Target	Outperform	$250.00 ➝ $275.00	Low	i Rating by Joshua Schimmer at Evercore ISI
5/29/2020	Oppenheimer	Initiated Coverage	Buy	$173.00 ➝ $166.00	Low	i Rating by Francois Brisebois at Oppenheimer Holdings Inc.
5/14/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$120.00 ➝ $154.00	High	i Rating by C. Duncan at Cantor Fitzgerald
5/12/2020	Needham & Company LLC	Reiterated Rating	Buy	$190.00	Medium	i
4/8/2020	Northland Securities	Initiated Coverage	Outperform	$128.00	High	i
3/5/2020	Citigroup	Initiated Coverage	Buy	$192.00	Medium	i
2/27/2020	HC Wainwright	Lower Price Target	Buy	$170.00 ➝ $161.00	High	i Rating by Douglas Tsao at HC Wainwright
2/26/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$174.00	High	i Rating by Charles Duncan at Cantor Fitzgerald
2/26/2020	Bank of America	Lower Price Target	Buy	$233.00 ➝ $227.00	High	i
2/26/2020	Oppenheimer	Lower Price Target	Outperform	$203.00 ➝ $173.00	Low	i Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
2/26/2020	Needham & Company LLC	Lower Price Target	Buy	$200.00 ➝ $190.00	High	i Rating by Serge Belanger at Needham & Company LLC
2/7/2020	Evercore ISI	Initiated Coverage	Buy	$260.00	Medium	i Rating by Joshua Schimmer at Evercore ISI
1/2/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$134.00	Low	i
12/18/2019	HC Wainwright	Reiterated Rating	Buy	$170.00	Low	i Rating by Douglas Tsao at HC Wainwright
11/11/2019	Evercore ISI	Reiterated Rating	Buy		Medium	i
11/8/2019	HC Wainwright	Reiterated Rating	Buy		Low	i Rating by D. Tsao at HC Wainwright
11/6/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$174.00 ➝ $174.00	Low	i
11/6/2019	Oppenheimer	Lower Price Target	Outperform	$222.00	Low	i Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
10/30/2019	HC Wainwright	Initiated Coverage	Buy	$170.00	Low	i Rating by D. Tsao at HC Wainwright
10/21/2019	Needham & Company LLC	Initiated Coverage	Buy	$200.00	Medium	i
9/27/2019	Oppenheimer	Lower Price Target	Outperform	$239.00 ➝ $233.00	Low	i Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
9/25/2019	Bank of America	Reiterated Rating	Buy	$218.00	Medium	i
8/7/2019	Morgan Stanley	Boost Price Target	Overweight	$238.00	Low	i Rating by David Lebovitz at Morgan Stanley
8/7/2019	Oppenheimer	Boost Price Target	Buy	$234.00 ➝ $239.00	Low	i
7/26/2019	Cowen	Reiterated Rating	Buy	$200.00	Medium	i
5/8/2019	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$195.00	Low	i Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
5/8/2019	JPMorgan Chase & Co.	Upgrade	Market Perform ➝ Outperform		Low	i
5/7/2019	Guggenheim	Reiterated Rating	Buy ➝ Buy	$186.00 ➝ $222.00	Low	i Rating by Yatin Suneja at Guggenheim
5/7/2019	CIBC	Upgrade	Market Perform ➝ Outperform		High	i
5/7/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$185.00 ➝ $210.00	High	i
5/7/2019	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$180.00 ➝ $215.00	High	i
5/7/2019	Cantor Fitzgerald	Reiterated Rating	Positive ➝ Overweight	$196.00 ➝ $229.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
5/7/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$162.00 ➝ $234.00	High	i Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
4/29/2019	Oppenheimer	Boost Price Target		$142.00 ➝ $162.00	Low	i Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
4/9/2019	Morgan Stanley	Reiterated Rating	Buy		Low	i Rating by David Lebovitz at Morgan Stanley
3/18/2019	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$193.00 ➝ $196.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
2/27/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$193.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
2/27/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$185.00	High	i
2/22/2019	Guggenheim	Initiated Coverage	Buy	$178.00	High	i
1/7/2019	AltaCorp Capital	Reiterated Rating	Outperform		Medium	i Rating by D. Kideckel at AltaCorp Capital
1/2/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$134.00	High	i
12/11/2018	Oppenheimer	Initiated Coverage	Hold	$142.00 ➝ $142.00	Low	i Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
12/9/2018	Cantor Fitzgerald	Lower Price Target		$211.00 ➝ $193.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
12/4/2018	Cantor Fitzgerald	Reiterated Rating	Overweight		Low	i Rating by Elemer Piros at Cantor Fitzgerald
12/3/2018	Cantor Fitzgerald	Lower Price Target	Overweight ➝ Buy	$211.00 ➝ $193.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
11/27/2018	Cantor Fitzgerald	Set Price Target	Buy	$211.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
11/12/2018	SVB Leerink	Initiated Coverage	Outperform	$185.00	Low	i Rating by M. Goodman at SVB Leerink LLC
11/5/2018	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Overweight		Low	i
10/11/2018	Morgan Stanley	Set Price Target	Buy	$240.00 ➝ $227.00	High	i Rating by David Lebovitz at Morgan Stanley
9/28/2018	Bank of America	Reiterated Rating	Buy ➝ Buy	$181.00 ➝ $197.00	Medium	i
9/28/2018	Morgan Stanley	Boost Price Target	Overweight	$197.00 ➝ $240.00	High	i Rating by David Lebovitz at Morgan Stanley
9/27/2018	Cantor Fitzgerald	Set Price Target	Buy	$211.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
9/7/2018	Morgan Stanley	Set Price Target	Overweight ➝ Overweight	$197.00	Medium	i
8/14/2018	Stifel Nicolaus	Initiated Coverage	Buy	$181.00	Medium	i
8/8/2018	Cantor Fitzgerald	Lower Price Target	Overweight	$235.00 ➝ $211.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
7/12/2018	Cantor Fitzgerald	Set Price Target	Buy	$235.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
6/26/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$170.00 ➝ $200.00	High	i
5/9/2018	Cowen	Reiterated Rating	Buy	$165.00	Low	i
4/19/2018	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$192.00 ➝ $205.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
4/17/2018	Cantor Fitzgerald	Set Price Target	Buy	$192.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
2/21/2018	Cantor Fitzgerald	Set Price Target	Buy	$192.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
2/6/2018	Bank of America	Lower Price Target	Buy ➝ Buy	$154.00 ➝ $149.00	High	i
2/6/2018	SVB Leerink	Boost Price Target	Outperform ➝ Outperform	$153.00 ➝ $157.00	High	i
2/5/2018	Cantor Fitzgerald	Reiterated Rating	Buy ➝ Buy	$208.00 ➝ $192.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
1/23/2018	SVB Leerink	Reiterated Rating	Buy	$153.00	Medium	i
12/14/2017	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$174.00	Medium	i
12/4/2017	Cantor Fitzgerald	Set Price Target	Buy	$208.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
11/20/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$208.00	N/A	i Rating by Elemer Piros at Cantor Fitzgerald
11/14/2017	Bank of America	Lower Price Target	Buy	$160.00 ➝ $158.00	N/A	i
10/6/2017	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$124.00	N/A	i
10/2/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$208.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
10/2/2017	Cowen	Reiterated Rating	Outperform	$165.00	Medium	i
10/2/2017	SVB Leerink	Reiterated Rating	Outperform	$160.00 ➝ $153.00	Medium	i
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$154.00	Medium	i
8/10/2017	SVB Leerink	Reiterated Rating	Outperform	$162.00 ➝ $160.00	Medium	i
8/8/2017	Cantor Fitzgerald	Set Price Target	Buy	$208.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
8/8/2017	Maxim Group	Downgrade	Buy ➝ Hold	$61.00	High	i Rating by Gabrielle Zhou at Maxim Group
8/7/2017	Maxim Group	Set Price Target	Buy	$135.00	Low	i Rating by Gabrielle Zhou at Maxim Group
6/8/2017	Maxim Group	Set Price Target	Buy	$135.00	High	i Rating by Gabrielle Zhou at Maxim Group
5/25/2017	Maxim Group	Reiterated Rating	Buy	$135.00	Low	i Rating by Lauren Chung at Maxim Group
5/9/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$208.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
4/20/2017	Maxim Group	Initiated Coverage	Buy ➝ Buy	$135.00	Medium	i
2/22/2017	The Goldman Sachs Group	Reiterated Rating	Buy	$185.00	N/A	i
2/7/2017	Piper Jaffray Companies	Set Price Target	Buy	$147.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
2/7/2017	Cantor Fitzgerald	Set Price Target	Buy	$208.00	N/A	i Rating by Elemer Piros at Cantor Fitzgerald
2/6/2017	Cowen	Set Price Target	Buy	$135.00	N/A	i Rating by Phil Nadeau at Cowen Inc
1/13/2017	The Goldman Sachs Group	Initiated Coverage	Buy	$189.00	N/A	i
12/7/2016	Cowen	Reiterated Rating	Outperform	$135.00	N/A	i Rating by Phil Nadeau at Cowen Inc
12/5/2016	Cantor Fitzgerald	Boost Price Target	Buy	$182.00 ➝ $208.00	N/A	i Rating by elemer piros at Cantor Fitzgerald
12/4/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$147.00	N/A	i Rating by joshua schimmer at Piper Jaffray Companies
11/3/2016	SVB Leerink	Reiterated Rating	Buy	$162.00	N/A	i Rating by P. Matteis at SVB Leerink LLC
10/7/2016	The Goldman Sachs Group	Initiated Coverage	Buy	$189.00	N/A	i
10/4/2016	SVB Leerink	Initiated Coverage	Outperform	$162.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
9/27/2016	Cowen	Reiterated Rating	Outperform	$135.00	N/A	i Rating by Phil Nadeau at Cowen Inc
9/26/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$147.00	N/A	i Rating by joshua schimmer at Piper Jaffray Companies
9/26/2016	Cantor Fitzgerald	Boost Price Target	Buy	$165.00 ➝ $182.00	N/A	i Rating by elemer piros at Cantor Fitzgerald
9/25/2016	Morgan Stanley	Boost Price Target	Overweight	$152.00 ➝ $160.00	N/A	i Rating by Andrew Berens at Morgan Stanley
9/8/2016	Cantor Fitzgerald	Set Price Target	Buy	$165.00	N/A	i Rating by elemer piros at Cantor Fitzgerald
8/26/2016	Numis Securities	Upgrade	Sell ➝ Hold		N/A	i
8/13/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$147.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
8/9/2016	Cowen	Reiterated Rating	Buy	$135.00	N/A	i Rating by Phil Nadeau at Cowen Inc
8/9/2016	Cantor Fitzgerald	Lower Price Target	Buy	$181.00 ➝ $165.00	N/A	i
7/18/2016	Bank of America	Reiterated Rating	Buy	$153.00	N/A	i Rating by Tazeen Ahmad at Bank of America Co.
6/29/2016	SVB Leerink	Reiterated Rating	Outperform	$130.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
6/28/2016	The Goldman Sachs Group	Lower Price Target		$135.00 ➝ $105.00	N/A	i
6/28/2016	Morgan Stanley	Boost Price Target	Overweight	$149.00 ➝ $152.00	N/A	i Rating by Andrew Berens at Morgan Stanley
6/28/2016	Cantor Fitzgerald	Reiterated Rating	Buy		N/A	i
6/27/2016	Cowen	Reiterated Rating	Buy	$135.00	N/A	i Rating by Phil Nadeau at Cowen Inc
6/27/2016	SVB Leerink	Boost Price Target	Buy	$138.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
6/27/2016	Janney Montgomery Scott	Initiated Coverage	Sell		N/A	i
6/26/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$147.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
6/21/2016	SVB Leerink	Reiterated Rating	Buy	$130.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
6/10/2016	Morgan Stanley	Reiterated Rating	Buy	$149.00	N/A	i Rating by Andrew Berens at Morgan Stanley
6/2/2016	Cantor Fitzgerald	Initiated Coverage	Buy	$181.00	N/A	i Rating by E. Piros at Cantor Fitzgerald
5/5/2016	SVB Leerink	Reiterated Rating	Outperform	$130.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
4/19/2016	SVB Leerink	Reiterated Rating	Outperform	$130.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
4/17/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Phil Nadeau at Cowen Inc
4/1/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$147.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
3/20/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$147.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
3/16/2016	Bank of America	Reiterated Rating	Buy		N/A	i Rating by Tazeen Ahmad at Bank of America Co.
3/15/2016	Cowen	Reiterated Rating	Buy	$135.00	N/A	i Rating by Phil Nadeau at Cowen Inc
3/14/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
3/14/2016	Morgan Stanley	Reiterated Rating	Buy		N/A	i Rating by Andrew Berens at Morgan Stanley
3/14/2016	SVB Leerink	Boost Price Target	Outperform	$100.00 ➝ $130.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
3/14/2016	Roth Capital	Boost Price Target	Buy	$130.00 ➝ $160.00	N/A	i
3/3/2016	Numis Securities	Initiated Coverage	Sell		N/A	i
2/18/2016	SVB Leerink	Lower Price Target	Outperform	$129.00 ➝ $100.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC

(Data available from 1/15/2016 forward)

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Today's Range

Now: $135.73

$134.79

$141.50

50 Day Range

MA: $124.11

$114.91

$140.08

52 Week Range

Now: $135.73

$67.98

$144.00

Volume

379,913 shs

Average Volume

442,914 shs

Market Capitalization

$4.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15

Frequently Asked Questions

What sell-side analysts currently cover shares of GW Pharmaceuticals?

The following Wall Street research analysts have issued reports on GW Pharmaceuticals in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., Evercore ISI, Guggenheim, HC Wainwright, Needham & Company LLC, Northland Securities, Oppenheimer Holdings Inc., Raymond James, Stifel Nicolaus, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.

What is the current price target for GW Pharmaceuticals?

11 Wall Street analysts have set twelve-month price targets for GW Pharmaceuticals in the last year. Their average twelve-month price target is $188.09, suggesting a possible upside of 38.6%. Evercore ISI has the highest price target set, predicting GWPH will reach $275.00 in the next twelve months. Northland Securities has the lowest price target set, forecasting a price of $128.00 for GW Pharmaceuticals in the next year.

What is the current consensus analyst rating for GW Pharmaceuticals?

GW Pharmaceuticals currently has 3 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GWPH will outperform the market and that investors should add to their positions of GW Pharmaceuticals.

What other companies compete with GW Pharmaceuticals?

Other companies that are similar to GW Pharmaceuticals include BioMarin Pharmaceutical, Ono Pharmaceutical, Elanco Animal Health, Grifols, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, Mirati Therapeutics, Zai Lab, Bausch Health Companies, Jazz Pharmaceuticals, Ionis Pharmaceuticals, ACADIA Pharmaceuticals, Ascendis Pharma A/S, Ultragenyx Pharmaceutical and BridgeBio Pharma.

How do I contact GW Pharmaceuticals' investor relations team?

GW Pharmaceuticals' physical mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company's listed phone number is 44-12-2326-6800 and its investor relations email address is sschultz@gwpharm.com. The official website for GW Pharmaceuticals is www.gwpharm.com.

NASDAQ:GWPH - GW Pharmaceuticals Stock Price Target and Predictions

Analyst Price Target for GWPH

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of GW Pharmaceuticals?

What is the current price target for GW Pharmaceuticals?

What is the current consensus analyst rating for GW Pharmaceuticals?

What other companies compete with GW Pharmaceuticals?

How do I contact GW Pharmaceuticals' investor relations team?